Clinical trial
Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma
NCT02647515 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma
- Lead sponsor
- Ruijin Hospital
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- January 31, 2013
- Completion date
- December 31, 2014
- Enrollment
- 18 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.